» Articles » PMID: 35758831

Association of Methylenetetrahydrofolate Reductase () Gene Polymorphisms (C677T and A1298C) with Thyroid Dysfunction: A Meta-analysis and Trial Sequential Analysis

Overview
Specialty Endocrinology
Date 2022 Jun 27
PMID 35758831
Authors
Affiliations
Soon will be listed here.
Abstract

Recent studies have shown that two common methylenetetrahydrofolate reductase () gene polymorphisms (C677T and A1298C) might correlate with thyroid dysfunction, but the results remain inconsistent. We carried out a meta-analysis aiming to assess the relationship of both polymorphisms with thyroid dysfunction. The PubMed, EMBASE, CNKI (China National Knowledge Infrastructure), CBMdisc (China Biology Medicine disc), WeiPu and Wanfang databases were searched up to September 2021. Case-control and cohort studies on polymorphism and thyroid dysfunction were identified. Eight studies from six publications were finally included in our meta-analysis, including 817 patients and 566 controls. After pooled analysis, we found that the C677T polymorphism was associated with an increased risk of hypothyroidism (TT CC+CT/recessive model: OR = 2.07, 95% CI: 1.02-4.20, P = 0.04; TT CC/homozygote model: OR = 2.35, 95% CI: 1.13-4.86, P = 0.02), while trial sequential analysis (TSA) revealed that it could be a false positive result. The A1298C polymorphism was related to a decreased risk of hypothyroidism (C A/allele model: OR = 0.63, 95% CI: 0.44-0.92, P = 0.02; CC AC+AA/recessive model: OR = 0.42, 95% CI: 0.22-0.79, P = 0.007; CC AA/homozygote model: OR = 0.43, 95% CI: 0.25-0.85, P = 0.02), which was conclusive according to TSA. The results of this meta-analysis suggest that A1298C seems to be a protective factor for hypothyroidism, while the C677T polymorphism may be a risk factor. However, more well-designed studies with larger sample sizes are needed to obtain more reliable results of the association between the C677T polymorphism and hypothyroidism.

Citing Articles

Gene Polymorphisms and Cancer Risk in Children and Adolescents: A Systematic Review and Meta-Analysis.

Kolanis S, Kotanidou E, Tsinopoulou V, Georgiou E, Hatzipantelis E, Fidani L Children (Basel). 2025; 12(1).

PMID: 39857939 PMC: 11764102. DOI: 10.3390/children12010108.


MTHFR as a Novel Candidate Marker for Litter Size in Rabbits.

Yang J, Bao Z, Li J, Lu T, Cai J, Sun S Animals (Basel). 2024; 14(13).

PMID: 38998044 PMC: 11240429. DOI: 10.3390/ani14131930.


Homocysteine-Potential Novel Diagnostic Indicator of Health and Disease in Horses.

Golynski M, Metyk M, Ciszewska J, Szczepanik M, Fitch G, Beczkowski P Animals (Basel). 2023; 13(8).

PMID: 37106874 PMC: 10135347. DOI: 10.3390/ani13081311.


Is Melatonin the "Next Vitamin D"?: A Review of Emerging Science, Clinical Uses, Safety, and Dietary Supplements.

Minich D, Henning M, Darley C, Fahoum M, Schuler C, Frame J Nutrients. 2022; 14(19).

PMID: 36235587 PMC: 9571539. DOI: 10.3390/nu14193934.

References
1.
Mahesh M, Cheng G, Khalighi K . Association of Methylenetetrahydrofolate Reductase Polymorphism with Lower High-Density Lipoprotein Cholesterol Level. Ann Clin Lab Sci. 2019; 49(2):232-236. View

2.
Gunduz M, Gunduz E, Kircelli F, Okur N, Ozkaya M . Role of surrogate markers of atherosclerosis in clinical and subclinical thyroidism. Int J Endocrinol. 2012; 2012:109797. PMC: 3296143. DOI: 10.1155/2012/109797. View

3.
Klerk M, Verhoef P, Clarke R, Blom H, Kok F, Schouten E . MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 2002; 288(16):2023-31. DOI: 10.1001/jama.288.16.2023. View

4.
Ozmen B, Ozmen D, Parildar Z, Mutaf I, Turgan N, Bayindir O . Impact of renal function or folate status on altered plasma homocysteine levels in hypothyroidism. Endocr J. 2006; 53(1):119-24. DOI: 10.1507/endocrj.53.119. View

5.
Allam M, El-Zawawy H, Barakat S, Ahmed S, Saleh R . A hidden cause of infertility in hypothyroid patients. Clin Case Rep. 2020; 8(2):374-378. PMC: 7044389. DOI: 10.1002/ccr3.2654. View